It appears that the biopharmaceutical industry's innovation engine is back on track and making up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's Center for Drug Evaluation and Research (CDER) green light, the fewest number for five years. (See BioWorld Insight, Dec. 27, 2016.) Read More
Since the mid-point of this year investors have cooled on biotech equities with the BioWorld Biopharmaceutical Index slipping 4 percent in value over this period. It was a different story for the first six months, with the index growing a healthy 14 percent. This dramatic swing in sentiment took its toll on stock valuations with 44 percent of the biopharmas companies registering a drop in their share price over the year. Read More
